Document is current
Any future updates will be listed below
-
Authors
Quint, Paula http://orcid.org/0009-0007-1463-1961
Schroeter, Christina B.
Kohle, Felix
Öztürk, Menekse
Meisel, Andreas
Tamburrino, Giuliano
Mausberg, Anne K.
Szepanowski, Fabian
Afzali, Ali Maisam
Fischer, Katinka
Nelke, Christopher
Räuber, Saskia
Voth, Jan
Masanneck, Lars
Willison, Alice
Vogelsang, Anna
Hemmer, Bernhard
Berthele, Achim
Schroeter, Michael
Hartung, Hans-Peter
Pawlitzki, Marc
Schreiber, Stefanie
Stettner, Mark
Maus, Uwe
Meuth, Sven G.
Stascheit, Frauke
Ruck, Tobias
-
Funding
Funding for this research was provided by:
Universitätsklinikum Düsseldorf. Anstalt öffentlichen Rechts
- License Information
-
More Information
Article History
Received: 15 March 2024
Revised: 25 June 2024
Accepted: 26 June 2024
First Online: 11 July 2024
Declarations
:
: MSc has received speaker honoraria from Alexion Pharmaceuticals, argenx, Bayer, Biogen, CSL Behring, Genzyme, Grifols, Merck, Miltenyi Biotec, Novartis, Roche, Teva, and Hormosan Pharma. He is vice chairman of the medical advisory board of the German Myasthenia Gravis Society. HPH received fees for serving on SC from Octapharma and Sanofi. MS served on the scientifc advisory boards and/or received speaker honoraria, travel funding or honoraria for medical writing from Argenex; Bayer; Biogen Idec; Biotest; CSL Behring; Genzyme; Grifols; Immunovant; Kedrion; Merck; Novartis; Octapharma; PPTA; Roche; Sanofi-Aventis; TEVA; UCB. FS received speaking honoria and honoria for attendance of advisory boards from argnx. The other authors have no conflicts of interest to declare.
: We confirm that all human studies have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
